Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orgenesis's average Accounts Receivable for the
three
months ended in Dec. 2024 was $0.10 Mil. Orgenesis's Revenue for the
three
months ended in Dec. 2024 was $0.30 Mil.
Hence, Orgenesis's Days Sales Outstanding for the
three
months ended in Dec. 2024 was 30.47.
The historical rank and industry rank for Orgenesis's Days Sales Outstanding or its related term are showing as below:
ORGS's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94 * Ranked among companies with meaningful Days Sales Outstanding only.
Orgenesis's Days Sales Outstanding
declined
from Dec. 2023 (43.97) to Dec. 2024 (30.47).
Orgenesis (OTCPK:ORGS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Orgenesis Days Sales Outstanding Related Terms
Orgenesis Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Orgenesis's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORGS vs ENDV, GBLX, OMGAQ: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Orgenesis's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orgenesis's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Orgenesis's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (ORGS) has a Days Sales Outstanding of 30.47 as of Dec. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Orgenesis and its competitors.
Is Orgenesis' Days Sales Outstanding too high?
Orgenesis' current Days Sales Outstanding is 30.47. The Biotechnology industry median Days Sales Outstanding is 68.94. Orgenesis' value of 30.47 is 55.8% below this industry median. Overall, Orgenesis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Orgenesis' Days Sales Outstanding compare to ENDV and GBLX?
Orgenesis' Days Sales Outstanding of 30.47 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.94. Orgenesis' value of 30.47 is 55.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orgenesis's current Days Sales Outstanding of 30.47 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Orgenesis and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orgenesis's current Days Sales Outstanding is 30.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orgenesis stock overvalued right now?
Orgenesis (ORGS) has a current Days Sales Outstanding of 30.47. The current Days Sales Outstanding is 30.47 and 55.8% below the Biotechnology industry median of 68.94. Orgenesis' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Orgenesis (ORGS), the current Days Sales Outstanding is 30.47 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score
Get the complete analysis for ORGS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGS has been successfully added to your 
